MIMEDX Announces Launch of EPIXPRESS®

Core Insights - MiMedx Group, Inc. has launched EPIXPRESS®, a new lyophilized human placental allograft aimed at enhancing its Advanced Wound Care (AWC) product portfolio [1][2] Product Overview - EPIXPRESS is designed to treat acute and chronic hard-to-heal wounds, featuring a tri-layer configuration and fenestrations for improved fluid movement [2][3] - The product is suitable for various conditions, including diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs), and is effective for deep or tunneling wounds [2][3] Company Background - MiMedx is a leader in the wound care sector, focusing on innovative solutions for chronic and hard-to-heal wounds, with a vision to be the global provider of healing solutions [4]